Honolulu, Hawaii 2021-12-07 13:39:39 –
((((Hill) – Pharmaceutical company GlaxoSmithKline (GSK) announced positive results from a phase 3 trial of a plant-based coronavirus vaccine on Tuesday.
The vaccine has an overall efficacy rate of 71% against all variants of the Sars-CoV-2 virus except Omicron and about 75% efficacy against diseases caused by the virus COVID-19. ..
Find more news on COVID-19: Cases, Vaccinations Coronavirus news page
GSK has partnered with Canadian biopharmacy company Medicago to develop a new vaccine against the coronavirus. Medicago, which developed the vaccine using a GSK adjuvant or an additional substance to improve the vaccine, will immediately submit the test data and seek approval from Health Canada, the national regulatory agency. The process of applying for urgent approval has already begun in the United States and the United Kingdom. GSK said in a press release..
“This is a great moment for both Medicago and the new vaccine platform,” Medicago President Takashi Nagao said in a statement. “The results of our clinical trials show the power of plant-based vaccine manufacturing technology. If approved, we will contribute to the battle of the world. COVID-19 Pandemic The world’s first plant-based vaccine for use on humans. “
Vaccine trials were conducted on 24,000 adults across six countries. Patients under study did not report any serious or adverse symptoms.
The results show that the double dose vaccine is particularly effective compared to other approved vaccines because it was tested in a “SARS-CoV-2 mutant-dominated environment” such as gamma and dominant delta. I am.
Both Medicago and GSK have used virus-like particles, a technology 30 years ago, to produce protein vaccines. Living plants are used as bioreactors to produce non-infectious protein particles that mimic the original structure of the virus, thus enhancing the immune system’s response to the invading virus.Medicago states that it uses plant species for vaccines Nicotiana benthamiana tobacco, Relatives of tobacco plants.
Medicago is developing many plant-based vaccines to combat seasonal flu and norovirus...And GSK has a common vaccine made from virus-like particles Vaccination against hepatitis b..
Plant-based vaccines are usually cheaper to manufacture and safer for patients. GSK said the new vaccine will be easier to distribute because it does not need to be stored at unusually low temperatures like the Moderna and Pfizer vaccines.
Check out what’s happening all over our country National news page
In a statement, GSK Chief Global Health Officer Thomas Breuer said, “The global COVID-19 pandemic, along with the current advantages of the Delta variant, the upcoming Omicron, and other variants that may continue in the future. , Continues to show new aspects. “.. “”The combination of GSK’s established pandemic adjuvant and Medicago’s plant-based vaccine technology is very likely to be an effective and refrigerator-stable option to help protect people from SARS-CoV-2. “
Plant-based coronavirus vaccine shows ‘positive efficacy and safety results,’ developers say Source link Plant-based coronavirus vaccine shows ‘positive efficacy and safety results,’ developers say